International Journal of Health Sciences and Research
[Indexed, Peer-Reviewed Journal]
Volume 15; Issue: 2; February 2025
Website: www.ijhsr.org
Review Article *ISSN: 2249-9571*

Pathophysiology and Clinical Perception of Immune Dysregulation in Chronic Liver Disease Accelerated by Acute Kidney Injury

P. Kishore Kumar[1], Bagadam Aparna[1], K. Mallikarjun Rao[1], Syed Mohiuddin Quadri[1], Tadikonda Rama Rao[2]

[1]Associate Professor, CMR College of Pharmacy, Kandlakoya-501401, Hyderabad, Telangana.
[1]Student, CMR College of Pharmacy, Kandlakoya-501401, Hyderabad, Telangana.
[2]Principal & Professor, CMR College of Pharmacy, Kandlakoya-501401, Hyderabad, Telangana.

Corresponding Author: Dr. P. Kishore Kumar

DOI: https://doi.org/10.52403/ijhsr.20250232

ABSTRACT

Abstraction Immune dysfunction, in particular cirrhosis-associated immune dysfunction (CAID), has been associated to chronic liver disease (CLD), a global health concern the fact that places patients vulnerable for infections and systemic inflammation. Because of variables like hepatorenal syndrome, sepsis, and hypovolemia, acute kidney injury (AKI) commonly exacerbates immune-mediated dysregulation and complicates chronic renal failure (CLD). This review examines the complicated relationship between immune system dysfunction and AKI in CLD. T-cell exhaustion and impaired B-cell activity influence adaptive immunity in CLD, while faulty neutrophils, monocytes, and natural killer cells describe poor innate immunity. By generating damage-associated molecular patterns (DAMPs) and advancing cytokine storms, AKI aggravates these processes, leading to immune-mediated paralysis and systemic inflammation. This review highlights the critical need for mechanistic studies, early diagnostic tools, and customised therapeutic approaches to mitigate the profound impact of AKI on immune dysfunction in CLD and improve patient outcomes. The combined consequences of CLD and AKI enhance the likelihood of serious illnesses, like spontaneous bacterial peritonitis and sepsis, and contribute to adverse clinical outcomes, including greater mortality and prolonged being hospitalised. Rising biomarkers and therapies, such as probiotics and anti-inflammatory agents, offer promising avenues for managing immune dysfunction in AKI-CLD interplay.

Keywords: DAMP, Immune dysfunction, adaptive immunity, Innate immunity

INTRODUCTION

Chronic liver disease comprises an ongoing decline of liver function. [1] It has evolved as one of the most prevalent causes of death among individuals worldwide and presents an imminent risk to health. Despite there are various explanations how CLDs take place, some of the more serious and prominent causes are viral hepatitis (HCV and HBV), autoimmune hepatitis, obesity/metabolic ailments, and abusing alcohol. [2] It is estimated that there are approximately 1.5 billion cases of CLD globally, which includes individuals at various stages of the disease's severity. Prevalent disease is most commonly caused by. ALD (2%) is followed

by HBV (29%), HCV (9%), and NAFLD (59%). One percent of cases are caused by other liver illnesses, such as fundamental biliary cholangitis, chronic sclerosing cholangitis, alpha-1 antitrypsin deficiency, Wilson's disease, and autoimmune hepatitis.[3]

In accordance to 69% of people in the 1999–2000 National Health and Nutrition Examination Survey database in the United States were not aware they had cirrhosis, and the prevalence was 0.27%, or 633,323 adults. Aspartate transaminase-platelet ratio >2 and abnormal liver function test results are used to diagnose cirrhosis. were independently correlated with a variety of aspects: male gender, older age, alcoholics, chronic HBV and HCV infection, and diabetes mellitus. Over a span of two years, the worldwide mortality rate for cirrhosis was 26.4%. Chronic hepatitis B is not anymore, the main risk factor of adult cirrhosis in India; alcohol has stepped into precedence. [4]

Acute kidney injury (AKI), an assortment of diseases, can be identified primarily changes in the output of urine and serum creatinine concentration. The RIFLE criteria advocate for Risk, Injury, Failure, Loss of Kidney Function, and End-stage Kidney Disease have taken over the term "acute renal failure" (ARF) in the preceding few years. The criteria regarding Kidney Disease Improving Global Outcomes (KDIGO) for AKI eventually took its place. [5] AKI is a sophisticated syndrome consisting of various pathophysiological processes, like acute glomerular illnesses, acute obstructive nephropathy, acute necrosis of the tubules, acute interstitial nephritis, and pre-renal AKI. [6]

Chronic liver disease and cirrhosis are frequently associated with acute kidney failure (AKI), that may be associated with several kinds of phenotypes. Patients with advanced liver disease tend to exhibit prerenal dysfunction owing to severe hypoalbuminemia. [7]

AKI has been associated to a poor prognosis and is a significant indicator of short-term mortality in LC patients. Evidence has shown that it's prevalence among hospitalized LC patients can vary between 20 to 50 percent. [8]

IMMUNE DYSFUNCTION IN CLD AND AKI

Immune dysfunction in CLD: Cirrhosis itself induces immune system dysfunction along with immunological-mediated inflammatory responses, demonstrating the dual immune system's function in the emergence of cirrhosis. Hepatocyte injuries by alcohol, viral infections, or autoimmunity is processed by the immune system, and this stimulates hepatic stellate cells resulting in fibrogenesis. Moreover, the immune system becomes compromised by cirrhosis, with dysregulated immune cell activation and an inability to guard the body against bacterial infection. [9] A medical condition termed cirrhosis-associated immune dysfunction syndrome is often observed, characterized by immunological paralysis or immune deficiencies. The severity of organ failure, bacterial translocation, and liver insufficiency coincides with the extent of immunological dysfunction associated with cirrhosis. [10]

Impact of AKI on Immune function:

Acute kidney impairment, as well as AKI, is a medical condition highlighted by an abrupt worsening in renal function, causing metabolic waste to pile up the fluid and electrolyte balance to get improperly regulated. AKI has considerable systemic impacts, primarily on the immune-mediated system, as well as to its local effects on the kidneys. activation within the innate immune system, damage-associated molecular patterns (DAMPs), and adaptive immunity dysregulation belong to immunological reactions which can be set off by AKI. [11]

Multiple organ dysfunction, elevated susceptibility to infections, and systemic inflammation may result through this immune-mediated dysregulation known as "immune-kidney crosstalk," the reciprocating relationship between AKI and

immune function accentuates the essential function that immune system reactions perform in the pathophysiology of AKI and its implications. [12]

INNATE IMMUNE DYSFUNCTION IN CHRONIC LIVER DISEASE

Establishing a bridge with acquired immunity, the innate immune system eliminates invading bacteria from the host by promoting the production of antimicrobial peptides and inflammatory mediators. Furthermore, the innate immune response sustains the microbiota of the intestinal tract, intestinal epithelial cell proliferation and apoptosis, and liver regeneration upon liver mass loss in an ideal condition of tissue and organ homeostasis. However, "harmful inflammation" that results in sepsis, chronic inflammation, autoimmune conditions, tissue and organ damage, fibrosis, and carcinogenesis is often caused by aberrant activation of innate immune activation. [13]

Toll-like Receptor (TLR) dysregulation and impaired pathogen recognition:

Toll-like receptors (TLRs) have been preserved through evolution receptors which are belonging to the pattern recognition receptor (PRR) family. These receptors are necessary for immune-mediated responses, especially when the extracellular matrix identifies a pathogen. For the purpose of to eliminate infectious organisms and cancer debris, TLRs regulate immediate inflammatory responses and stimulate innate or adaptive immune responses. [14]

Adaptive immunity dysfunction in CLD

The adaptive immune system is thought to be equally compromised in CLD. Reduction in T-cell activation and proliferation hinders the immune response to infections as well as any other injury or disease of the body. This state presents with high T-cell exhaustion over-expression, typical PD-1, and CTLA4 among other high inhibitory receptor expressions which render the capability of T-cells less active against pathogens.

Also noteworthy is the B-cell dysfunction, another substantial part, where the antibody production is greatly impaired. This deficiency in the humoral immunity results in further omission of intervening measures against the infectious agents, which means CLD patients could be exposed to recurrent and severe infections. [15]

c. Micromicrobial Translocation and Gut-Liver Axis

Jo gut-liver axis at the kumitka na tayong immune dysfunction toyinjo aktemake hi to glucieitary fungal dia lichimetratychis. Gut dysbiosis dhekore t constituted ay fluctuate normal intestinal flora and aygued-permeability in choir enpatighbactharor so the translocate incnasites as lipopolysaccharides-LPS is insystematic circulation. The activation of these pathogen-associated molecular patterns (PAMPs) in turn modulates toll-like receptors (TLRs) on immune cells, thus triggering an inflammatory cascade.

This is amplified in CLD, where the liver can't clear any of these bacterial products anymore, resulting in ongoing systemic inflammation. The persistent activation of Toll-like receptors (TLRs) and the subsequent release of pro-inflammatory mediators set off a detrimental cycle that leads to immune dysfunction and liver damage. [16]

d. Systemic Inflammation and Chronic Liver Disease (CLD) Immune Paralysis]

Chronic low-level inflammation is a hallmark of chronic liver disease (CLD). along with an unusual state of immune paralysis. Persistent DAMPs that persistently circulate, which are released from necrotic liver cells, and also circulating PAMPs are the main contributors of inflammation to initiate this systemic inflammation. Such inflammatory milieu promotes liver damage and multi-organ dysfunction.

On the other side, inflammatory factors paralyze the immune system from responding effectively to new infections. This mesmerizing duality of chronic

inflammation and immune exhaustion significantly predisposes CLD patients to what can be termed as a "sepsis-friendly" environment, wherein easiness and rapidity of progression of severe infections are well observed leading to equally poor outcomes. [17]

Pathophysiology of AKI in CLD:

Types of AKI:

Functional AKI:

It refers to the kidney injury without any significant structural damage to the renal parenchyma. It is primarily due to haemodynamic alterations decreasing glomerular filtration rate and renal perfusion. This type of AKI is majorly seen in the patients with portal hypertension with CLD that causes redistribution of blood flow with splanchnic vasodilation which is usually mediated by increased prostaglandins, nitric oxide levels along with other vasodilatory substances.

This results in decreased renal perfusion of kidneys and systemic hypotension leading to Renin-Angiotensin-Aldosterone system activation, causing vasoconstriction of renal arterioles and sodium retention. The decreased renal perfusion leads to worsening of GFR.

All of this results in Sympathetic Nervous System (SNS) activation which further increases vasoconstriction, impairing blood flow to the kidneys.

This can lead to Hepatorenal Syndrome (HRS-AKI) which is the severe form of functional AKI characterized by larger extent of renal vasoconstriction, extreme sodium retention and oliguria.

Absence of significant proteinuria or presence of cells in urine is seen. This sets a stage for structural AKI too but there is no direct structural AKI present. However, this is reversible with restoration of haemodynamic stability. [18]

Structural AKI:

Structural AKI attacks the renal parenchyma, including the tubules, glomeruli, or interstitium, directly. On one hand, functional AKI would tend to recover on the treatment however, structural AKI will cause irreversible damage if timely intervention does not take place.

The understanding of pathophysiology mainly involves:

Acute Tubular Necrosis (ATN): Most common causes of structural AKI in CLD. Prolonged ischemia due to sustained renal hypoperfusion or sepsis leads to necrosis of tubular epithelial cells.

Mechanisms:

phosphorylation injury and damage to hypoperfusion.

Cytotoxic damage due to circulating inflammatory mediators and oxidative stress.

Clinical findings: Presence of granular casts and epithelial cells in urine.

Glomerulonephritis: Immune-mediated injury to the glomeruli, which usually follows the precipitation of circulating immune complexes or infectious agents.

Example: Membranoproliferative glomerulonephritis in the context of cryoglobulinemia associated with hepatitis C. [19]

Acute interstitial Nephritis (AIN): Immune-mediated inflammatory reaction involving the renal interstitium and is most often associated with drugs and infectious agents.

Pathology: Infiltration of inflammatory cells within the renal interstitium.

Sepsis-Associated AKI: Systemic inflammation in sepsis leads to endothelial injury, microvascular thrombosis, and even the direct cytotoxicity of renal cells. [20]

Mixed AKI

It is a mix of functional and structural kidney injury. This dual-type presentation is commonly observed in CLD because of the overlapping effect of hemodynamic disturbances and systemic inflammation.

Pathophysiology:

- Functional Component:

Prolonged hemodynamic instability (for example, splanchnic vasodilation, RAAS

activation) leads to renal hypoperfusion, predisposing to structural injury.

- Structural Component:

Extended ischemia consequent to hypoperfusion leads to acute tubular necrosis (ATN), exacerbated by the systemic inflammation and oxidative stress induced by sepsis.

- Mixed AKI usually occurs in CLD patients with infections, like spontaneous bacterial peritonitis (SBP) or sepsis.

Clinical Features:

- Mixed AKI for these types of presentation:
- Decreased perfusion, with elements of the functional component.
- Tubular injury features that compose structural components. [21]

Mechanisms through which Acute Kidney Injury (AKI) occurs in Chronic Liver Disease (CLD)

determining the biological processes that trigger AKI cultivates in CLD is vital for more timely intervention to improve outcomes. The main mechanisms at play include hemodynamic changes, systemic inflammation, and infection-induced factors.

1. Hemodynamic Changes

Set mostly around functional AKI, hemodynamic changes are critical in the process leading to AKI in CLD. Most of these changes occur because of portal hypertension, which is an important sign of advanced CLD and may give rise to splanchnic vasodilation. The vasodilation arises from the excessive production of vasodilatory substances, including nitric oxide, prostaglandins, and carbon monoxide. As a result, a compensatory activation of the sympathetic nervous system (SNS), non-osmotic release of vasopressin, and the stimulation of the renin-angiotensin-aldosterone system (RAAS) all adopt place.as the splanchnic circulation expands. In the long run, these mechanisms will lead to intense renal vasoconstriction, a reduction in renal blood flow with a decrease in the global filtration rate (GFR) on its part. Thus, due to the faulty perfusion of kidneys, this will manifest clinical signs as hepatorenal syndrome (HRS). While HRS is not considered structural kidney damage, it is potentially reversible as long as the liver failure and hemodynamic derangements are directly rectified. [7]

2. Systemic Inflammation

Another primary pathophysiologic mechanism of AKI in CLD is systemic inflammation. The development of liver disease activates innate immune responses and subsequently releases a tumor necrosis factor-alpha (TNF-α) alongside other pro-inflammatory cytokines, interleukins (IL-6 and IL-8), and interferons. These cytokines would aggravate oxidative stress and endothelial dysfunction by rendering renal endothelial integrity impaired.

Furthermore, the overall metabolic response may be turbocharged by bacterial translocation through the gut due to increased gut permeability and impaired immunity. Chronic inflammation modifies renal microcirculation, preceding glomerular damage and tubular dysfunction. Persistent inflammatory signaling sets in motion further renal damage during acute stressors such as infections or hypovolemia. [22]

3. AKI meets with Exacerbation by Infection

Throughout history, infections-in particular SBP and sepsis-have formed common links and immediate triggers for AKI in individuals with long-term liver disease. They accelerate the systemic inflammatory response, whereby vasodilatation and reduced effective arterial blood volume lead to renal hypoperfusion.

In chronic liver disease, the infection denotes a dysregulated immune response which entails excessive cytokine production that disturbs vascular tone and coagulation. The septic environment worsens ischemia and tubular injury. In patients with cirrhosis and ascites, SBP-induced multisystem derangement makes hemodynamic instability worse, enabling splanchnic vasodilatation and activating systemic endotoxemia. This is followed by renal hypoperfusion and ischemia, providing a

context whereby the risk for development of AKI is markedly raised. [23]

* Taken together, these diverse mechanisms in the form of hemodynamic alterations, systematic inflammatory involvement, and infections provide the perfect storm for the development of chronic liver disease alongside AKI.The vasodilatation in the splanchnic bed resulting in renal hypoperfusion is the basis for the functional impairment of kidney function, whilst structural damage to the kidney may happen due to the immune compromise where systemic inflammation and infections aggravate the risk. Understanding of these mechanisms is vital so that treatment can be best optimized to manage any potential AKI, including hemodynamic support, infection management, and decreased systemic inflammation in patients with chronic liver disease

Effects of AKI on Systemic Physiology

Acute kidney injury remains a life-threatening complication whose effects go far beyond renal function. Along with impaired renal function, the influence of AKI spreads throughout systemic physiology, mainly through the retention of uremic toxins and disturbances of fluid and electrolyte balance. Such changes could lead to immune disablement, up-regulation of systemic inflammation, and progression to multi-organ failure. [24]

Uremic Toxins

The accumulation of uremic toxins is characteristic of AKI. In a functionally competent kidney, toxins like urea and creatinine, and Protein-bound solutes that includes p-cresyl and indoxyl sulfate are efficiently eliminated. In AKI, inability of glomeruli to filter, or tubular secretory and reabsorption activity, leads to a retention of uremic toxins in blood. [25]

Cellular Dysfunction

Uremic toxins have a potent inhibitory effect on immune cell function. For example, P-cresyl sulfate and indoxyl sulfate prohibit neutrophils and macrophages compared to executing essential functions of phagocytosis and cytokines production. This immunosuppression further increases the risk of secondary infections, a frequent source of morbidity and mortality in patients with AKI. [26]

Worsening Systemic Inflammation

Besides the immunosuppression action, uremic toxins actively fuel systemic inflammation. By causing a release of pro-inflammatory cytokines involving interleukins (IL-6) and tumor necrosis factor-alpha (TNF-α) from immune and endothelial cells, an inflammatory milieu evolves, which may not only worsen ongoing kidney injury, but also initiate endothelial cell injury and capillary leak, resulting in further tissue swelling and organ hypoperfusion. [27]

Neurotoxic Effects

Uremic toxins also impair the functioning of the central nervous system, resulting in encephalopathy. Cognitive dysfunction, reduced consciousness, and seizures are produced when they interfere with neurotransmitter balance and neuronal signaling. This neurotoxicity synergistically increases the challenges faced in the management of critically ill AKI patients. [28]

Fluid and Electrolyte Disturbances

These events could bestow wide-ranging implications for AKI, such as an impaired immunity that accentuates multi-organ failure.

Volume overload

The kidneys will not drop sodium and water; instead, fluid accumulates, leading to pulmonary edema. This impending edema obstructs the exchange of oxygen during breathing and later necessitates the redistribution of blood from the heart. Pressure in the liver and gut venous systems may also serve to thwart perfusion, thus further exacerbating some complications seen systemically.

Electrolyte abnormalities:

Hyperkalemia: This is a potassium retention phenomenon whereby potassium accumulates terribly and endangers the life of the case through deadly arrhythmias arising from aberration in cardiac electrical activations.

Hyponatremia: Underwater imbalance leading to osmotic dilution of aqueous concentration results in a syndrome of hyponatremia. As a result, brain edema sets in; symptoms such as confusion and seizures develop.

Hypocalcemia and Hyperphosphatemia: The metabolic derangement leads to a calcium-phosphate disorder in AKI coupled with the biochemical affinity role of signaling within inflammation and immune function.

Acid-Base Imbalance

In general, metabolic acidosis comes in as an acute complication in AKI due to excess hydrogen ion; the renal inability to regenerate bicarbonate. Acid-base imbalance impairs cell metabolism and causes cellular toxicity by reducing myocardial contraction performance and attempting to dampen the potency of any immune responses that could save the life of a diagnosed AKI patient.[29]

Multi-organ failure

A torrent of uremic toxins, alongside a truckload of inflammatory response components along with fluid and electrolyte disturbances, sets off a cascade sequence that leads to multi-organ failure.

Cardiovascular System: Fluid overload and electrolyte disturbance will, in the long run, potentiate failure, arrhythmias, increase vascular stiffness, atherosclerosis-uremic toxins into the mix.

Respiratory system: The respiratory system includes pulmonary edema from volume overload that disturbs gas exchange and results in hypoxemia and respiratory failure.

Liver and Gut: For the liver and gut, the reduced perfusion only worsens liver dysfunction and intestinal permeability, opening them to bacterial translocation and systemic endotoxemia.

Immune system: Impaired immune responses increase the risk of infection and sepsis, both among the leading causes of death in severe renal damage patients. [30]

Acute Kidney Injury and the Immune Function in Chronic Liver Disease

Acute kidney injury is an important adverse consequence of chronic liver disease, with substantial effects on the overall immune function and poor clinical outcomes. The interplay between these two coexisting entities creates a vicious cycle of inflammation, immune dysregulation, and increased risk for infection. This section explores some of the main ways in which acute kidney injury might worsen immune dysfunction in chronic liver disease.

Excerbation of Systemic Inflammation

Renal injury during acute kidney injury triggers the release of molecular patterns linked to damage, involving heat shock proteins, high-mobility group box 1 protein, and mitochondrial DNA. These molecules act as endogenous danger signals to enable the immune cells' pattern recognition receptors. This triggers the release interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) are manifestations of pro-inflammatory cytokines.

Activity of systemic Pro-inflammatory cytokines embrace interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) because of the conditions of microbiological translocation, gut dysbiosis, and hepatic dysfunction. In association, acute kidney injury exerts further inflammatory load above and beyond any pre-existing state. This creates a self-reinforcing feedback loop whereby inflammation worsens renal injury, accentuating the emission of additional molecular patterns linked to damage, which eventually results in perpetuation of immune dysregulation. The augmented systemic inflammatory state promotes endothelial dysfunction, tissue edema, and multi-organ failure.[22]

Dysregulation of Innate Immune Function
In acute kidney injury, the first line of defense against infectious agents through the innate immune system is severely impaired.

Neutrophils
Neutrophil dysfunction is, therefore, the central element of immune dysregulation in acute kidney injury. The impaired neutrophil phagocytosis of bacteria leaves the host vulnerable to infection. At the same time, the exaggerated NETosis, a process which concludes in the formation of neutrophil extracellular traps, or NETs, extensively damages host tissue and sets into motion microvascular thrombosis. Such paradoxical dysfunction indeed will increase system

Monocytes and Macrophages
Monocyte and macrophage activation is called during acute kidney injury (AKI), resulting in the overproduction of pro-inflammatory cell signalling molecules like TNF alpha, IL-6 and IL-12. While these cytokines are important for host defence against pathogens, their augmented concentrations during AKI exacerbate systemic inflammation and immune dysfunction. Such an amplified coding response also adds fuel to the fire of advancing liver inflammation during chronic liver disease (CLD).

Natural Killer (NK) Cells
NK cells are the primary mediators of infected or malignantly transformed cell death. However, the citotoxicity of NK cells gets significantly impaired in AKI. Less IFN gamma expression by NK cells further dampens clearances of infections, which leaves patients with CLD quite vulnerable to opportunistic pathogens. [31]

Impairments of the Adaptive Immune Response
The adaptive immune system, crucial for targeted and long-lasting immunity, is also significantly compromised during AKI.

a. T-Cell Exhaustion
Because of prolonged inflammation and accumulation of uremic toxins, T-cell exhaustion is reached in AKI. This is characterized by declining T-cell production, activation, and proliferation of cytokines. Already compromised in their efficacy in CLD, this accomplishes a further detriment to immune responses against available pathogens.

b. Regulatory T Cells
T-Cells are the most important for immune homeostasis through the suppression of excessive inflammatory processes. In AKI, Tregs get overactivated, and this may create an imbalance in immune regulation. Such a suppression would worsen the state of immune paralysis and disposition to infections, while harmful pathogens may not be cleared properly.

c. B cells
AKI will also alter B-cell functions leading to dysfunctional antibody production that will jeopardize the humoral immune response hence affect clearance of infections. In the case of CLD, where bacterial translocation is frequent, this will further reduce antibody production and expose patients to bloodstream infection and sepsis risk. [31]

AKI and Risk of Infection
Another complication of great consequence from AKI vulnerability to infection, which contributes significantly to the death rate in chronic liver disease (CLD) patients. [32]

Bacterial Translocation
In CLD, the gut barrier dysfunction and overgrowth of gut bacteria set the stage for translocation of bacteria into the bloodstream. AKI adds to this by causing intestinal ischemia and further damaging mucosal integrity. The resulting scenario carries with it the risk of systemic infections, such as spontaneous bacterial peritonitis and bacteremia. [33]

Opportunistic Infections and Sepsis

A combination of systemic inflammation, immune cell dysfunction, and impaired adaptive immunity make such patients particularly vulnerable to multiple opportunistic infections. Therefore, when associated with events occurring in a compromised host, blood-borne, supplemented by infections with Escherichia coli, Klebsiella, and Candida, can yield sepsis in such a state. Such infections are responsible for poor response to treatment and the extent of the damage includes direct malfunctioning of hemostatic processes by attending septic shock and death. [34]

*AKI is reported as an enhancer, eliciting systemic inflammation, hindering both adaptive and innate immunity and infection susceptibility in patients of CLD. DAMPs further aggravate the inflammatory process, and in addition, uremic toxins and dysregulated immune cells will have impede pathogen clearance. This potentiality of worsening the patient management process due to the indirect compromise of these immune functions, raises the risk of sepsis when infections set in. Hence more so is the value that he is timely recognition and intervention to decrease AKI's effect on the immune system, culminating in an overall better prognosis for such high-risk patients. [22]

Clinical implications of immunity dysfunction in AKI and CLD interplays.

Coincidence of chronic liver disease and acute kidney injury (AKI) presents a canine undertone-as clinical challenge owing to the intertwining pathophysiological mechanisms. Immune dysfunction holds itself a very pivotal part in this comorbidity, generating immense variations in prognosis and management. [35]

Complications of Immune Dysfunction in the AKI-CLD Interplay, Increased Incidence of Infections: Advanced chronic liver disease (CLD)-many a time, a state termed `immune paresis'-on account of dysregulation of the immune system-often coupled with AKI-makes the patient highly susceptible to infections. Other common infections include Bacterial translocation from the gut brings about spontaneous bacterial peritonitis (SBP) to the peritoneal cavity: pneumonia acts as a common complication in hospitalized patients having profound liver diseases. The combined action of AKI in CLD increases the risk for sepsis, which is represented by a systemic inflammatory response to infection that may rapidly lead to multi-organ failure.

Worsening of systemic inflammation: AKI in the context of chronic liver disease (CLD) very much exaggerates systemic inflammation, resulting in complications such as hepatic encephalopathy (HE). A neuropsychiatric disorder provoked by the accumulation of toxins, especially ammonia, because the liver and the kidneys are incapable of anyone working efficiently to eliminate it. Added to inflammatory turmoil, the risk for subsequent multiple organ failure also translates into a momentous event in squandering patient care. [36]

Prognostic Implications of AKI Within CLD.It has pronouncedly increased the mortality rates: AKI is representative enough as an independent factor for dictating both the short-term and long-term mortality incidences in patients having CLD. Patients floating AKI have reported remarkable declines in survival rates. Short-term mortality finds itself accountable for acute complications such as septic shock or circulatory failure; however, long-term mortality finds accountability generally when recurrent organ failure or recurrent infections intervenes.

The interactions between AKI and CLD often mean such patients truly need extended monitoring and management that sometimes lead to increased rates of ICU admissions. The majority of such cases have prolonged stays in the hospital due to compounded complexity, repeated complications, and difficulty in achieving stable clinical improvement. Not only does this have an impact upon patients individually, but it creates a substantial burden upon the systems of healthcare. [37]

Management Challenges

Limited Options for Managing Immune Dysfunction

In AKI-CLD patients, the immune dysfunction is multifactorial: defective function of neutrophils, increased cytokines product, and defective complement activity. Nevertheless, the therapies directed at immune dysfunction are rather limited. The use of prophylactic antibiotics against SBP or sepsis is standard practice, but there are disadvantages, such as acquisition of antibiotic-resistant mutations.

Challenges in Using Immunosuppressants or Anti-inflammatory Therapies

Treating inflammation in patients with CLD is especially challenging because of the need for very fine balancing. Immunosuppressive or anti-inflammatory agents can theoretically help in tempering the exaggerated immune response, but the consequences are usually very risky in patients with CLD. These therapies greatly increase the chances of infection that represents another cause of morbidity and mortality among this population. Furthermore, inflammation-targeting agents may also exert detrimental effects on the liver and, hence, endanger liver function. The limited therapeutic options and the risks associated with existing treatments highlight an urgent need for research into novel interventions to mitigate immune dysfunction and improve outcomes for patients with AKI and CLD. [38]

EMERGING INSIGHTS AND THERAPEUTIC PERSPECTIVES:

Biomarkers for AKI and immune system

-RENAL BIOMARKERS-

Imaging tests, serum or urine components, or any other quantifiable measurement can all be

considered accessible signs of AKI. Urine incorporates the most promising markers for early AKI detection, so further characterization is anticipated to turn these markers toward practical tools for early diagnosis. Injury mechanism identification, and site and severity assessment. It is hoped that one or more of these biomarkers, either by themselves or in conjunction, can help with early diagnosis, focused intervention, and tracking the course and remission of the condition. [39]

Other kidney indicators have been identified and confirmed in various patient groups. They differ in their kinetics, distribution, physiological function, and the cells from which they come. Urinary biomarkers fall into three major types. Biomarkers with low molecular weights that are easily filtered in the glomerulus include light chains, cystatin C, β2-microglobulin, lysozyme, and α1-microglobulin. When kidney damage occurs, renal cells upregulate a second set of indicators. Among these compounds are kidney injury molecule-1 (KIM-1), Dickkopf-3 (DKK3), and monomeric neutrophil gelatinase associated lipocalin (NGAL). Finally, when inflammatory cells reach the kidneys during AKI, they may release biomarkers. IL-9 and interleukin-18 (IL-18) are two examples. [40]

NGAL Biomarker Neutrophil gelatinase-associated lipocalin (NGAL) represents a 25 kDa protein. It may generate It was initially identified in kidney tubular cells and may produce NGAL in response to various stressors. It has been discovered to contribute to post-injury tubular regeneration and kidney development. It was discovered that tubular damage caused it to be highly expressed. Acute kidney damage (AKI) has been found to be predicted early by urine NGAL in later clinical studies. [41]

Cystatin C-All nucleated cells continuously produceCystatin C (CysC), a low-molecular-weight (13.3 kDa) protein that is freely filtered by the glomerulus and fully metabolized by the proximal tubule. It is being studied as a novel endogenous serum biomarker that is sensitive for the early assessment of eGFR changes as a filtration marker.

Kidney injury molecule-1 (KIM-1) is a type I transmembrane glycoprotein that is widely produced at the apical membranes of proximal epithelial cells in tubules during tissue regeneration after toxic or ischemic

acute kidney injury. It is also produced when tubular epithelial cells dedifferentiate. [42]

IMMUINE BIOMARKERS-

A wide range of medical indicators known as biomarkers can be evaluated objectively to identify various medical conditions or how a patient is responding to an intervention. As such, they can serve as endpoints in clinical research as well as for fundamental diagnostic and therapy prognosis. analyzing the application of biomarkers in clinical and scientific settings. As long as they can be routinely and accurately recorded and analyzed, biomarkers can include proteins, metabolites, nucleic acids, and even photographs.

Since cytokines are tiny molecules that coordinate immune responses, they hold considerable promise as biomarkers in the human and veterinary domains. We will concentrate on protein detection as a field for biomarker discovery due to its significant prevalence in clinical applications and convenience of blood collecting. New technology advancements like digital ELISA, which have resulted in notable sensitivity gains, make this possible. [43]

Therapeutic targets for AKI-CLD

Immune dysfunction:

Damage-associated molecular patterns (DAMPs) are somewhat immune cells activated due to an increase in proinflammatory mediators which include interleukin (IL)-6, tumor necrosis factor (TNF)-α, and IL-1β. The aforementioned DAMPs bring about the release of proinflammatory cytokines with the value as TNF-α, IL-1α, and IL-6. Which trigger theThe progressive loss of kidney function during chronic kidney disease (CKD) is negatively correlated with the release of proinflammatory cytokines comprising TNF-α, IL-1α, and IL-6. This is particularly true for markers that correspond to inflammation, among them fibrinogen and C-reactive protein (CRP). These cytokines encourage T cell activation in conjunction with tissue factors.[44]

Changes in the Gut-Liver Axis

Probiotics: Probiotics lower intestinal permeability, restore the balance of the gut microbiota, and lessen endotoxemia—all of which are linked to liver illnesses like cirrhosis and non alcoholic fatty liver disease. According to certain research, probiotics like strains of Lactobacillus and Bifidobacterium improve inflammatory indicators and liver function.

Role of organ crosstalk in therapeutic development:

Systemic circumstances like ischemia, oxidative stress, and metabolic acidosis allow the kidneys and liver to communicate with each other in both directions. Thus, kidney-liver communication may lead to either liver-induced renal disease or kidney-induced liver damage.

kidney-liver interference. Due to systemic influences affecting both organs, Crosstalk between the urinary tract and liver is a dynamic, two-way exchange. Numerous factors, covering ischemia and reperfusion, cytokine release, pro-inflammatory signaling pathways, metabolic acidosis, oxidative stress, and alterations in enzyme activity and metabolic pathways, govern the association between the kidneys and liver. ARF encompasses a tendency to progress to CRF, which can be recognized by a gradual reduction in renal clearance and glomerular filtration. Acute renal failure (CRF), chronic renal failure (NAFLD), nonalcoholic fatty liver disease (NASH), nonalcoholic steatohepatitis (MAFLD), triglycerides (RAAS), renin-angiotensin-aldosterone system (ROS), reactive oxygen species, low-density lipoprotein (HDL), high-density lipoprotein (TG), and metabolically associated LDL fatty liver diseases.[45]

The most commonly used extracorporeal therapy techniques that help patients with acute or chronic renal insufficiency survive are haemodialysis and hemofiltration (intermittent or continuous). On the other side, they cause an unwanted inflammatory reaction, which is summed up as bioincompatibility, to varying degrees. [46]

FUTURE DIRECTIONS

- Important research gaps: Mechanistic investigations of AKI's effects on CLD immunity

-Function of Inflammatory Mediators: Although certain biomarkers, such NGAL, are increased in AKI and may be suggestive of kidney damage, it is unclear how they affect immune responses in CLD patients during AKI.

-Effects on Particular Immune Cell Populations: In the context of CLD patients, the liver-kidney axis is rarely used to describe the effects of AKI on particular immune cell populations, specifically the neutrophils, T cells, and macrophages.

-Therapeutic Interventions Focussing on Immune Modulation: Research on therapies that alter immune responses to lessen the impact of AKI in CLD is few.

-It is unknown how long-term immunological alterations brought on by AKI may impact how liver disease develops and the
patient's prognosis. [47]

- developing focused treatments to control immunological dysfunction

-Immune Response Modification in Acute-on-Chronic Liver Failure (ACLF):
Immune dysfunction and systemic inflammation are characteristics of ACLF. Among the therapeutic strategies are immune cell function modulation, bacterial translocation reduction, and dysbiosis correction. Possible strategies include:

-Changes to the Gut Microbiota: Taking probiotics or antibiotics can help the flora return to normal and lower inflammation throughout the body.

-Anti-inflammatory Therapies: To prevent immune suppression, medicines that target specific inflammation pathways are used.

-Immune cell modulation is the development of treatments that improve pathogen clearance and lower susceptibility to infections by enhancing the activity of immune cells, such as neutrophils and macrophages. [7]

-The significance of tailoring medication to treat AKI-CLD interchangeably:

Personalised medicine adapts medical treatment to each patient's particular needs. This would be essential for managing the intricate relationships between AKI and CLD, which would include taking lifestyle, environmental, and genetic factors into account during therapy.

Clinicians can evaluate individual risk profiles thanks to personalised medication, which makes it more straightforward to determine which patients are at risk for AKI early on. This strategy will enable prompt therapies to prevent or lessen renal impairment by identifying patients early.

To put it simply, personalised medicine offers a strong framework for taking into account the intricate relationship between AKI and CLD. This method will help to ensure better diagnostic skills, optimise therapy, and improve overall patient care by emphasising the unique qualities that distinguish each patient. [7]

CONCLUSION

In chronic liver disease (CLD), immunological dysfunction and acute kidney injury (AKI) cooperate to generate a synergistic pathophysiological cycle that enhances potential to infections, exacerbates systemic inflammation, and interferes with immune defensive measures. AKI contributes to the immune dysregulation which is common to CLD by releasing damage-associated molecular patterns (DAMPs), transforming cytokine storms, and compounding adaptive and innate immune difficulties. This cascade not only exacerbates the clinical outcomes, such as increased infection rates and mortality, but also demonstrates the obstacles of managing patients with both ailments.

Declaration by Authors

Ethical Approval: Not Applicable
Acknowledgement: None
Source of Funding: None
Conflict of Interest: The authors declare no conflict of interest.

REFERENCES

1. Sharma A, Nagalli S. Chronic Liver Disease. 2023 Jul 3. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32119484.
2. De Siervi S, Cannito S, Turato C. Chronic Liver Disease: Latest Research in Pathogenesis, Detection and Treatment. International Journal of Molecular Sciences [Internet]. 2023 Jan 1;24(13):10633. Available from: https://www.mdpi.com/1422-0067/24/13/10633
3. Cheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. Clinical Liver Disease. 2021 May;17(5):365–70.
4. Premkumar M, Anand AC. Overview of Complications in Cirrhosis. Journal of Clinical and Experimental Hepatology. 2022 Jul;12(4):1150–74.
5. Tamargo C, Hanouneh M, Cervantes CE. Treatment of Acute Kidney Injury: A Review of Current Approaches and Emerging Innovations. Journal of Clinical Medicine [Internet]. 2024 Jan 1;13(9):2455. Available from: https://www.mdpi.com/2077-0383/13/9/2455
6. Gameiro J, Fonseca JA, Outerelo C, Lopes JA. Acute Kidney Injury: from Diagnosis to Prevention and Treatment Strategies. Journal of Clinical Medicine [Internet]. 2020 Jun 2;9(6):1704. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357116/
7. Chancharoenthana W, Leelahavanichkul A. Acute kidney injury spectrum in patients with chronic liver disease: Where do we stand? World Journal of Gastroenterology [Internet]. 2019b Jul 28;25(28):3684–703. Available from: https://www.wjgnet.com/1007-9327/full/v25/i28/3684.htm
8. Thapa P, KC S, Hamal AB, Sharma D, Khadka S, Karki N, et al. Prevalence of Acute Kidney Injury in Patients with Liver Cirrhosis. Journal of Nepal Medical Association. 2020 Aug 31;58(228).
9. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology. 2014 Dec;61(6):1385–96.
10. Elda Hasa, Phillipp Hartmann, Bernd Schnabl, Liver cirrhosis and immune dysfunction, *International Immunology*, Volume 34, Issue 9, September 2022, Pages 455–466.
11. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. Journal of Clinical Investigation. 2011 Nov 1;121(11):4210–21.
12. Jang HR, Rabb H. Immune cells in experimental acute kidney injury. Nature Reviews Nephrology. 2014 Oct 21;11(2):88–101.
13. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. The Journal of Physiology. 2012 Jan 27;590(3):447–58.
14. Sameer AS, Nissar S. Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. Durmaz B, editor. BioMed Research International [Internet]. 2021 Sep 12;2021(1157023):1–14. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452412/
15. Singbartl K, Formeck CL, Kellum JA. Kidney-Immune System Crosstalk in AKI. Semin Nephrol. 2019 Jan;39(1):96-106. doi: 10.1016/j.semnephrol.2018.10.007. PMID: 30606411.
16. De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells. 2021 Oct 30;10(11):2959. doi: 10.3390/cells10112959. PMID: 34831182; PMCID: PMC8616442.
17. Kronsten VT, Shawcross DL. Clinical Implications of Inflammation in Patients With Cirrhosis. Am J Gastroenterol. 2025 Jan 1;120(1):65-74. doi: 10.14309/ajg.0000000000003056. Epub 2024 Aug 27. PMID: 39194320; PMCID: PMC11676607.
18. Belcher JM, Parikh CR, Garcia-Tsao G. Acute kidney injury in patients with cirrhosis: perils and promise. Clin Gastroenterol Hepatol. 2013 Dec;11(12):1550-8. doi: 10.1016/j.cgh.2013.03.018. Epub 2013 Apr 10. PMID: 23583467; PMCID: PMC3840046.
19. Nadim MK, Kellum JA, Forni L, Francoz C, Asrani SK, Ostermann M, Allegretti AS, Neyra JA, Olson JC, Piano S, VanWagner

LB, Verna EC, Akcan-Arikan A, Angeli P, Belcher JM, Biggins SW, Deep A, Garcia-Tsao G, Genyk YS, Gines P, Kamath PS, Kane-Gill SL, Kaushik M, Lumlertgul N, Macedo E, Maiwall R, Marciano S, Pichler RH, Ronco C, Tandon P, Velez JQ, Mehta RL, Durand F. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol. 2024 Jul;81(1):163-183. doi: 10.1016/j.jhep.2024.03.031. Epub 2024 Mar 26. PMID: 38527522; PMCID: PMC11193657.

20. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nature Reviews Disease Primers [Internet]. 2021 Jul 15;7(1). Available from: https://www.nature.com/articles/s41572-021-00284-z
21. Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. Journal of Hepatology. 2015 Apr;62(4):968–74.
22. Attieh RM, Wadei HM. Acute Kidney Injury in Liver Cirrhosis. Diagnostics (Basel). 2023 Jul 13;13(14):2361. doi: 10.3390/diagnostics13142361. PMID: 37510105; PMCID: PMC10377915.
23. Angeli P, Tonon M, Pilutti C, Morando F, Piano S. Sepsis-induced acute kidney injury in patients with cirrhosis. Hepatol Int. 2016 Jan;10(1):115-23. doi: 10.1007/s12072-015-9641-1. Epub 2015 Jul 4. PMID: 26141259.
24. Hoste EAJ, Corte WD. Clinical Consequences of Acute Kidney Injury. Controversies in Acute Kidney Injury [Internet]. 2011;174:56–64. Available from: https://www.karger.com/Article/Fulltext/329236
25. André C, Bodeau S, Kamel S, Bennis Y, Caillard P. The AKI-to-CKD Transition: The Role of Uremic Toxins. Int J Mol Sci. 2023 Nov 10;24(22):16152. doi: 10.3390/ijms242216152. PMID: 38003343; PMCID: PMC10671582.
26. Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017 May;5(2):127-137. doi: 10.1093/gastro/gox009. Epub 2017 Apr 24. PMID: 28533910; PMCID: PMC5421450.
27. Arroyo, V., Angeli, P., Moreau, R., Jalan, R., Clària, J., Trebicka, J., Fernández, J., Gustot, T., Caraceni, P., & Bernardi, M. (2021). The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. *Journal of Hepatology*, *74*(3), 670-685. https://doi.org/10.1016/j.jhep.2020.11.048
28. Pang H, Kumar S, Ely EW, Gezalian MM, Lahiri S. Acute kidney injury-associated delirium: a review of clinical and pathophysiological mechanisms. Critical Care. 2022 Aug 27;26(1).
29. Smith Y. Electrolyte Disturbance and Acute Kidney Failure [Internet]. News-Medical.net. 2016. Available from: https://www.news-medical.net/health/Electrolyte-disturbance-and-acute-kidney-failure.aspx.
30. CaseHippo Inc. CaseHippo [Internet]. Kidney.org. 2025 [cited 2025 Jan 16]. Available from: https://cme.kidney.org/spa/courses/resource/managing-aki-as-part-of-multi-organ-failure-in-patients-with-cirrhosis/mooc/home/default.
31. Lee, K., Jang, H.R. & Rabb, H. Lymphocytes and innate immune cells in acute kidney injury and repair. *Nat Rev Nephrol* 20, 789–805 (2024). https://doi.org/10.1038/s41581-024-00875-5.
32. Batte A, Shahrin L, Claure-Del Granado R, Luyckx VA, Conroy AL. Infections and Acute Kidney Injury: A Global Perspective. Semin Nephrol. 2023 Sep;43(5):151466. doi: 10.1016/j.semnephrol.2023.151466. Epub 2023 Dec 28. PMID: 38158245; PMCID: PMC11077556.
33. Rabb H, Pluznick J, Noel S. The Microbiome and Acute Kidney Injury. Nephron. 2018;140(2):120-123. doi: 10.1159/000490392. Epub 2018 Jun 29. PMID: 29961049; PMCID: PMC6292672
34. . Mysorekar VV, Eshwarappa M, Lingaraj U. Opportunistic infections in a renal transplant recipient. Infect Dis Rep. 2012 Jan 5;4(1):e8. doi: 10.4081/idr.2012.e8. PMID: 24470938; PMCID: PMC3892655.
35. Sato Y, Yanagita M. Immune cells and inflammation in AKI to CKD progression. American Journal of Physiology-Renal Physiology. 2018 Dec 1;315(6):F1501–12.
36. Stephen J McWilliam, Rachael D Wright, Gavin I Welsh, Jack Tuffin, Kelly L Budge,

Laura Swan, Thomas Wilm, Ioana-Roxana Martinas, James Littlewood, Louise Oni, The complex interplay between kidney injury and inflammation, *Clinical Kidney Journal*, Volume 14, Issue 3, March 2021, Pages 780–788, https://doi.org/10.1093/ckj/sfaa164

37. Pan HC, Chen HY, Teng NC, Yeh FY, Huang TM, Chun Yin See, et al. Recovery Dynamics and Prognosis After Dialysis for Acute Kidney Injury. JAMA network open. 2024 Mar 8;7(3):e240351–1.
38. Kaushal GP, Shah SV. Challenges and advances in the treatment of AKI. J Am Soc Nephrol. 2014 May;25(5):877-83. doi: 10.1681/ASN.2013070780. Epub 2014 Jan 30. PMID: 24480828; PMCID: PMC4005310.
39. Vaidya, V. S., Ferguson, M. A., & Bonventre, J. V. (2008). Biomarkers of acute kidney injury. *Annual Review of Pharmacology and Toxicology*, *48*(1), 463–493. https://doi.org/10.1146/annurev.pharmtox.48.113006.094615
40. Ostermann, M., Legrand, M., Meersch, M., Srisawat, N., Zarbock, A., & Kellum, J. A. (2024). Biomarkers in acute kidney injury. *Annals of Intensive Care*, *14*(1). https://doi.org/10.1186/s13613-024-01360-9
41. . Soni, S. S., Cruz, D., Bobek, I., Chionh, C. Y., Nalesso, F., Lentini, P., de Cal, M., Corradi, V., Virzi, G., & Ronco, C. (2010). NGAL: a biomarker of acute kidney injury and other systemic conditions. *International Urology and Nephrology*, *42*(1), 141–150. https://doi.org/10.1007/s11255-009-9608-z
42. Yahya, A., Kadhim, D., & Abdalhadi, N. (2023). Kidney injury molecule-1 and cystatin C as early biomarkers for renal dysfunction in Iraqi type 2 diabetes mellitus patients. *Journal of Advanced Biotechnology and Experimental Therapeutics*, *6*(3), 673. https://doi.org/10.5455/jabet.2023.d158
43. Llibre, A., & Duffy, D. (2018). Immune response biomarkers in human and veterinary research. *Comparative Immunology, Microbiology and Infectious Diseases*, *59*, 57–62. https://doi.org/10.1016/j.cimid.2018.09.008
44. Tinti, F., Lai, S., Noce, A., Rotondi, S., Marrone, G., Mazzaferro, S., Di Daniele, N., & Mitterhofer, A. P. (2021). Chronic kidney disease as a systemic inflammatory syndrome: Update on mechanisms involved and potential treatment. *Life (Basel, Switzerland)*, *11*(5), 419. https://doi.org/10.3390/life11050419
45. Rad, N. K., Heydari, Z., Tamimi, A. H., Zahmatkesh, E., Shpichka, A., Barekat, M., Timashev, P., Hossein-Khannazer, N., Hassan, M., & Vosough, M. (2024). Review on kidney-liver crosstalk: Pathophysiology of their disorders. *Cell Journal*, *26*(2), 98–111. https://doi.org/10.22074/cellj.2023.2007757.1376
46. Schlee H, Prondzinsky R, Osten B, Werdan K. Systemische Entzündungsreaktionen extrakorporaler Therapieverfahren (I): Hämodialyse und Hämofiltration [Systemic inflammatory reactions to extracorporeal therapy measures (I): Hemodialysis and hemofiltration]. Wien Klin Wochenschr. 1997 May 9;109(9):301-11. German. PMID: 9265388.
47. Cullaro, G., Kanduri, S. R., & Velez, J. C. Q. (2022). Acute kidney injury in patients with liver disease. *Clinical Journal of the American Society of Nephrology: CJASN*, *17*(11), 1674–1684. https://doi.org/10.2215/CJN.03040322

How to cite this article: P. Kishore Kumar, Bagadam Aparna, K. Mallikarjun Rao, Syed Mohiuddin Quadri, Tadikonda Rama Rao. Pathophysiology and clinical perception of immune dysregulation in chronic liver disease accelerated by acute kidney injury. *Int J Health Sci Res.* 2025; 15(2):241-255. DOI: *https://doi.org/10.52403/ijhsr.20250232*

******